245 related articles for article (PubMed ID: 34469831)
21. Discovery of BP3 as an efficacious proteolysis targeting chimera (PROTAC) degrader of HSP90 for treating breast cancer.
Liu Q; Tu G; Hu Y; Jiang Q; Liu J; Lin S; Yu Z; Li G; Wu X; Tang Y; Huang X; Xu J; Liu Y; Wu L
Eur J Med Chem; 2022 Jan; 228():114013. PubMed ID: 34864330
[TBL] [Abstract][Full Text] [Related]
22. Discovery of E3 Ligase Ligands for Target Protein Degradation.
Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and activity study of a novel PI3K degradation by hijacking VHL E3 ubiquitin ligase.
Wang H; Li C; Liu X; Ma M
Bioorg Med Chem; 2022 May; 61():116707. PubMed ID: 35344835
[TBL] [Abstract][Full Text] [Related]
24. Proteolysis targeting chimeras (PROTACs) in cancer therapy.
Ocaña A; Pandiella A
J Exp Clin Cancer Res; 2020 Sep; 39(1):189. PubMed ID: 32933565
[TBL] [Abstract][Full Text] [Related]
25. A selective BCL-X
Khan S; Zhang X; Lv D; Zhang Q; He Y; Zhang P; Liu X; Thummuri D; Yuan Y; Wiegand JS; Pei J; Zhang W; Sharma A; McCurdy CR; Kuruvilla VM; Baran N; Ferrando AA; Kim YM; Rogojina A; Houghton PJ; Huang G; Hromas R; Konopleva M; Zheng G; Zhou D
Nat Med; 2019 Dec; 25(12):1938-1947. PubMed ID: 31792461
[TBL] [Abstract][Full Text] [Related]
26. [NSD3 suppresses LPS-triggered TNF-α production via promoting the dimethylation of histone H3K36 in macrophages].
Liu Z; Cheng Q; Yang L; Sun Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2018 Jun; 34(6):481-487. PubMed ID: 30236198
[TBL] [Abstract][Full Text] [Related]
27. Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer.
Han X; Zhao L; Xiang W; Qin C; Miao B; McEachern D; Wang Y; Metwally H; Wang L; Matvekas A; Wen B; Sun D; Wang S
J Med Chem; 2021 Sep; 64(17):12831-12854. PubMed ID: 34431670
[TBL] [Abstract][Full Text] [Related]
28. Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein.
Zhou H; Bai L; Xu R; Zhao Y; Chen J; McEachern D; Chinnaswamy K; Wen B; Dai L; Kumar P; Yang CY; Liu Z; Wang M; Liu L; Meagher JL; Yi H; Sun D; Stuckey JA; Wang S
J Med Chem; 2019 Dec; 62(24):11280-11300. PubMed ID: 31747516
[TBL] [Abstract][Full Text] [Related]
29. Crystallization of VHL-based PROTAC-induced ternary complexes.
Wijaya AJ; Farnaby W; Ciulli A
Methods Enzymol; 2023; 681():241-263. PubMed ID: 36764760
[TBL] [Abstract][Full Text] [Related]
30. Discovery of novel VEGFR-2-PROTAC degraders based on the localization of lysine residues via recruiting VHL for the treatment of gastric cancer.
Wang XR; Wang S; Mu HX; Xu KY; Wang XT; Shi JT; Cui QH; Zhang LW; Chen SW
Eur J Med Chem; 2022 Dec; 244():114821. PubMed ID: 36242985
[TBL] [Abstract][Full Text] [Related]
31. Bivalent Ligands for Protein Degradation in Drug Discovery.
Scheepstra M; Hekking KFW; van Hijfte L; Folmer RHA
Comput Struct Biotechnol J; 2019; 17():160-176. PubMed ID: 30788082
[TBL] [Abstract][Full Text] [Related]
32. Low expression of NSD1, NSD2, and NSD3 define a subset of human papillomavirus-positive oral squamous carcinomas with unfavorable prognosis.
Gameiro SF; Ghasemi F; Zeng PYF; Mundi N; Howlett CJ; Plantinga P; Barrett JW; Nichols AC; Mymryk JS
Infect Agent Cancer; 2021 Feb; 16(1):13. PubMed ID: 33588906
[TBL] [Abstract][Full Text] [Related]
33. Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.
Han X; Zhao L; Xiang W; Qin C; Miao B; Xu T; Wang M; Yang CY; Chinnaswamy K; Stuckey J; Wang S
J Med Chem; 2019 Dec; 62(24):11218-11231. PubMed ID: 31804827
[TBL] [Abstract][Full Text] [Related]
34. Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins.
Shirasaki R; Matthews GM; Gandolfi S; de Matos Simoes R; Buckley DL; Raja Vora J; Sievers QL; Brüggenthies JB; Dashevsky O; Poarch H; Tang H; Bariteau MA; Sheffer M; Hu Y; Downey-Kopyscinski SL; Hengeveld PJ; Glassner BJ; Dhimolea E; Ott CJ; Zhang T; Kwiatkowski NP; Laubach JP; Schlossman RL; Richardson PG; Culhane AC; Groen RWJ; Fischer ES; Vazquez F; Tsherniak A; Hahn WC; Levy J; Auclair D; Licht JD; Keats JJ; Boise LH; Ebert BL; Bradner JE; Gray NS; Mitsiades CS
Cell Rep; 2021 Jan; 34(1):108532. PubMed ID: 33406420
[TBL] [Abstract][Full Text] [Related]
35. Recent Advances in PROTACs for Drug Targeted Protein Research.
Yao T; Xiao H; Wang H; Xu X
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142231
[TBL] [Abstract][Full Text] [Related]
36. Prospect of targeting lysine methyltransferase NSD3 for tumor therapy.
Li D; Tian T; Ko CN; Yang C
Pharmacol Res; 2023 Aug; 194():106839. PubMed ID: 37400043
[TBL] [Abstract][Full Text] [Related]
37. Recent Advances in the Design and Development of Anticancer Molecules based on PROTAC Technology.
Mukhamejanova Z; Tong Y; Xiang Q; Xu F; Pang J
Curr Med Chem; 2021; 28(7):1304-1327. PubMed ID: 32164504
[TBL] [Abstract][Full Text] [Related]
38. Discovery of a Potent and Selective Degrader for USP7.
Pei Y; Fu J; Shi Y; Zhang M; Luo G; Luo X; Song N; Mi T; Yang Y; Li J; Zhou Y; Zhou B
Angew Chem Int Ed Engl; 2022 Aug; 61(33):e202204395. PubMed ID: 35691827
[TBL] [Abstract][Full Text] [Related]
39. Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders.
Yang X; Wang Z; Pei Y; Song N; Xu L; Feng B; Wang H; Luo X; Hu X; Qiu X; Feng H; Yang Y; Zhou Y; Li J; Zhou B
Eur J Med Chem; 2021 Jun; 218():113341. PubMed ID: 33780898
[TBL] [Abstract][Full Text] [Related]
40. The PROTAC selectively degrading Bcl-x
Zhang S; Chen Y; Xu Z; Yang J; Sun R; Wang J; Sun Y; Jiang B; Yang X; Tan W
Theranostics; 2022; 12(17):7476-7490. PubMed ID: 36438482
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
